Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Two-Target antibody for eczema tested in early trial

NCT ID NCT05859724

Disease control Sponsor: Yellow Jersey Therapeutics AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either the drug or a placebo. The main goal was to check safety and how the drug moves through the body. The trial was terminated, so full results may not be available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NM26-2198 (a bispecific antibody targeting IL-4R and IL-31)
What this could lead to
If successful, this could point toward a new treatment option for moderate-to-severe atopic dermatitis that targets two inflammatory pathways at once.
What could go wrong
This was a very early (Phase 1) study focused on safety and dosing, not yet on effectiveness. The trial was terminated, so results may be limited or inconclusive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

126 people

The number who actually took part.

Started

May 2023

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. SAD: Non-Asian ethnicity with grandparents and parents of non-Asian descent or Japanese descent having all four Japanese grandparents born in Japan. 2. SAD and MAD in Healthy Volunteers: Male or female aged 18 to 55 years; MAD: Male or female ≥18 years of age. 3. ALL COHORTS: Weight of 45 kg to 100 kg and BMI of 18.0 to 30.0 kg/m2. 4. SAD and MAD in Healthy Volunteers: Non-childbearing, non-breastfeeding females or males willing to use double barrier contraception or abstention from sex and sperm donation during the study; MAD: Males willing to use double barrier contraception or abstention from sex and sperm donation during the study; non-childbearing females or females of childbearing potential using protocol-defined method contraception, and who is not pregnant, lactating, or breastfeeding. 5. MAD: Diagnosis of chronic AD. 6. MAD: EASI score ≥16. 7. MAD: vIGA-AD™ score of ≥3. 8. MAD: Atopic lesions cover ≥10% of body surface area (BSA). 9. MAD: PP-NRS score ≥4. 10. MAD: Daily use of non-prescription emollient. Note: Other protocol-defined Inclusion criteria apply. Exclusion Criteria: 1. SAD and MAD in Healthy Volunteers: Any clinically-relevant medical history or lab abnormality, including positive test for SARS-CoV-2, Hepatitis B or C, or HIV; MAD: Clinically-significant, abnormal laboratory findings, or positive test for SARS-CoV-2, Hepatitis B or C, or HIV. 2. ALL COHORTS: Clinically important ECG abnormalities or history/evidence thereof. 3. SAD and MAD in Healthy Volunteers: Use of prescription or non-prescription medications (except occasional use of paracetamol). 4. MAD: Diagnosis of protocol-specified skin diseases other than AD, or history of other significant skin condition that could interfere with study assessments. 5. MAD: History or ongoing allergy/hypersensitivity or history, or history of hypersensitivity to biological drugs. 6. MAD: Recent receipt of immunoglobulin or blood products. 7. MAD: Recent treatment with protocol-specified investigational treatments, or any prior treatment with dupilumab, tralokinumab, lebrikizumab, nemolizumab, or other protocol-specified drugs. 8. MAD: AD with recent ocular involvement requiring chronic ocular corticosteroid treatment. 9. MAD: Chronic pruritis due to conditions other than AD. 10. MAD: Acute AD superinfection, recent superficial skin infection, or other chronic/acute infection requiring protocol-defined treatments. 11. MAD: Recent use of sedating antihistimines, systemic corticosteroids, cytotoxic treatments, other immunosuppressive/immunomodulating agents, and other protocol-specified prohibited medications. 12. MAD: Recent topical corticosteroid or prescription moisturizer use. Note: Other protocol-defined Exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • COPERNICUS Podmiot Leczniczy Sp. z o.o., Szpital Sw. Wojciecha

    Gdansk, 80-462, Poland

  • California Clinical Trials Medical Group (CCTMG) managed by Parexel

    Glendale, California, 91206, United States

  • Centre de Recherche Saint-Louis

    Québec, G1W4R4, Canada

  • D&H Tamarac Research Center

    Tamarac, Florida, 33321, United States

  • DermEffects

    London, Ontario, N6H5L5, Canada

  • First OC Dermatology Research

    Fountain Valley, California, 92708, United States

  • Klinika Ambroziak Dermatologia

    Warsaw, 02-953, Poland

  • Paddington Testing Co.

    Philadelphia, Pennsylvania, 19103, United States

  • Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych

    Warsaw, 02-507, Poland

  • Sadick Research Group

    New York, New York, 10075, United States

  • TCR Medical Corporation

    San Diego, California, 92123, United States

  • UK-SH - Lübeck

    Lübeck, Schleswig-Holstein, 23538, Germany

  • Universitätsklinikum Carl Gustav Carus

    Dresden, Saxony, 01307, Germany

  • Universitätsmedizin Mainz

    Mainz, Hesse, 55131, Germany

  • Uniwersytecki Szpital Kliniczny im. F.Chopina w Rzeszowie

    Rzeszów, 35-055, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.